Medicinal Chemistry Support Program for Therapeutic Development

The National Institutes of Health’s National Institute on Neurological Disorders and Stroke, through the NIH Blueprint Neurotherapeutics Network, is planning a sole-source modification to an existing IDIQ contract with Curia Global, Inc. to continue medicinal chemistry support for therapeutic development. The work covers project management and reporting, compound logistics, synthesis, computational chemistry, and in vitro ADMET studies in support of preclinical drug discovery, including exploratory, hit-to-lead, and lead optimization activities. The contractor must be able to support ongoing projects across those chemistry stages, provide the personnel and facilities needed for medicinal chemistry planning and synthesis, and handle repository-related storage, access training, and IT security for existing compound materials; the ordering period remains March 16, 2018 through March 15, 2028. Interested parties may submit capability statements or objections, and responses must be emailed to Shaun Rostad by 1:00 p.m. EDT on June 4, 2026, with notice number HHSN271201800001I referenced; fax responses will not be accepted.